ASND (Ascendis Pharma AS) Ending Cash Position: $662 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASND Ascendis Pharma AS ASND
37 GF Score
Price $261.00
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Ending Cash Position?

Ascendis Pharma AS ASND +0.47% 37 Ending Cash Position is $662 Mil as of Mar. 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

Ascendis Pharma AS's Ending Cash Position for the quarter that ended in Mar. 2026 was $662 Mil.

Ascendis Pharma AS's quarterly Ending Cash Position increased from Sep. 2025 ($633 Mil) to Dec. 2025 ($721 Mil) but then declined from Dec. 2025 ($721 Mil) to Mar. 2026 ($662 Mil).

Ascendis Pharma AS's annual Ending Cash Position increased from Dec. 2023 ($428 Mil) to Dec. 2024 ($586 Mil) and increased from Dec. 2024 ($586 Mil) to Dec. 2025 ($721 Mil).

Ascendis Pharma AS Ending Cash Position Related Terms

Ascendis Pharma AS Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Ending Cash Position Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 504.26 471.15 427.66 585.91 721.36

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 559.92 569.83 632.74 721.36 662.22
ASND
37GF Score
Ascendis Pharma AS ASND
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Ascendis Pharma AS's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=655.202+66.157
=721

Ascendis Pharma AS's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=712.187+-49.967
=662

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $662 Mil mean?
Ascendis Pharma AS (ASND) has a Ending Cash Position of $662 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Ending Cash Position too high?
Ascendis Pharma AS's current Ending Cash Position is $662 Mil. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Ending Cash Position compare to JAZZ and BBIO?
Ascendis Pharma AS's Ending Cash Position of $662 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Ending Cash Position is $662 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Ending Cash Position of $662 Mil. The current Ending Cash Position is $662 Mil. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Ending Cash Position is $662 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges A1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for ASND

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$261.00
Price